Imaging Technologies Top Agenda for Critical Path Effort at FDA | GenomeWeb

SAN FRANCISCO, April 21 (GenomeWeb News) - The US Food and Drug Administration believes certain imaging technologies can help drug makers track the behavior of fluorescent probes and monitor drug response rates in clinical trials, according to a senior FDA official.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.